Alpha 1 Antitrypsin Inhibits Dendritic Cell Activation and Attenuates Nephritis in a Mouse Model of Lupus
S. Elshikha, Ahmed
Mahdi, Mahmoud A.
- Publisher: Figshare
Molecular Biology | lupus-prone mouse model | over-reactive dendritic cells | bm-derived dc differentiation | tlr 9 agonist | Ecology | 69999 Biological Sciences not elsewhere classified | haat treatment | function | Immunology | tlr 4 agonist | type 1 diabetes | il | alpha 1 antitrypsin inhibits dendritic cell activation | Developmental Biology | mrl | tnf | sle | lps | serum autoantibody levels | Hematology | Cell Biology | arthritis mouse models | Biochemistry | Cancer | ifn-i | activation
mesheuropmc: skin and connective tissue diseases | immune system diseases
<div><p>Systemic lupus erythematosus (SLE) is an autoimmune disorder with a worldwide distribution and considerable mortality and morbidity. Although the pathogenesis of this disease remains elusive, over-reactive dendritic cells (DCs) play a critical role in the disease development. It has been shown that human alpha-1 antitrypsin (hAAT) has protective effects in type 1 diabetes and rheumatoid arthritis mouse models. In the present study, we tested the effect of AAT on DC differentiation and functions, as well as its protective effect in a lupus-prone mouse model. We showed that hAAT treatment significantly inhibited LPS (TLR4 agonist) and CpG (TLR9 agonist) -induced bone-marrow (BM)-derived conventional and plasmacytoid DC (cDC and pDC) activation and reduced the production of inflammatory cytokines including IFN-I, TNF-α and IL-1β. In MRL/lpr mice, hAAT treatment significantly reduced BM-derived DC differentiation, serum autoantibody levels, and importantly attenuated renal pathology. Our results for the first time demonstrate that hAAT inhibits DC activation and function, and it also attenuates autoimmunity and renal damage in the MRL/lpr lupus model. These results imply that hAAT has a therapeutic potential for the treatment of SLE in humans.</p></div>